STOCKHOLM--(BUSINESS WIRE)--Regulatory News: In connection with the acquisition of Corvette Pharmaceutical Services Group completed on October 1, 2014, Recipharm AB (STO: RECI)(“Recipharm”) issued convertible bonds with a nominal value of EUR 50 million as part of the financing of the acquisition. The convertible bonds can be converted into up to 5,030,549 class B-shares. The holders of the convertible bonds have agreed to a lock-up in respect of the new shares issued upon conversion until 14 February, 2015.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.